#Icad nashua nh registration
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may also be obtained from Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-9544, or by email at continues 333-253808) filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, on March 2, 2021, which registration statement became automatically effective upon filing.Ī final prospectus supplement relating to the offering dated Mawas filed with the SEC on Maand is available on the SEC’s website at. 333-235887) previously filed with the Securities and Exchange Commission (“SEC”) on January 10, 2020, which registration statement was declared effective on Januand an additional registration statement on Form S-3MEF (File No. The securities described above were offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. and Colliers Securities LLC acted as co-managers for the offering. JMP Securities, Craig-Hallum Capital Group, and Lake Street Capital Markets, LLC acted as lead managers for the offering and Laidlaw & Company (UK) Ltd. Guggenheim Securities acted as sole book-running manager for the offering. The Company intends to use the net proceeds of the offering for working capital and general corporate purposes. The Company received total gross proceeds from the offering (before deducting the underwriting discounts and offering expenses) of approximately $25.0 million.
#Icad nashua nh full
(the “Company”, NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the closing on Maof its previously announced underwritten public offering of 1,393,738 shares of common stock at a public offering price of $18.00 per share, which included the exercise in full by the underwriters of their option to purchase up to an additional 171,516 shares of common stock.
NASHUA, N.H., Ma(GLOBE NEWSWIRE) - iCAD, Inc.